Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Rilimogene galvacirepvec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 19 Jan 2018 Planned End Date changed from 30 May 2019 to 31 May 2019.
- 19 Jan 2018 Planned primary completion date changed from 30 May 2019 to 31 May 2019.
- 19 Jan 2018 Status changed from recruiting to active, no longer recruiting.